Our present work reveals that the silencing of PHD3, which occurs during glioma progression, primarily affects tumor growth by different mechanisms that do not depend on HIF, but centre around the control of EGFR activity, resulting in a net stimulation of cell growth coupled to reduced apoptosis. The gene discussed is EGLN3; the disease is neoplasm.